Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats

Cancer Research

Volumn 65, Issue 10, 2005, Pages 4300-4308

  Hoving, Saske ^a   Brunstein, Flavia ^a   Aan De Wiel Ambagtsheer, Gisela ^a   Van Tiel, Sandra T ^a   De Boeck, Gert ^b   De Bruijn, Ernst A ^b   Eggermont, Alexander M M ^a   Ten Hagen, Timo L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTHELIN 1; MELPHALAN; MESSENGER RNA; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL INJURY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TUMOR LEVEL; EDEMA; ERYTHROCYTE; EXTRAVASATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LIMB PERFUSION; MACROPHAGE; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; SOFT TISSUE SARCOMA; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAPILLARY PERMEABILITY; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENDOTHELIAL CELLS; HINDLIMB; HYDROGEN-ION CONCENTRATION; INTERLEUKIN-2; LEUKOCYTES; MACROPHAGES; MALE; MELPHALAN; RATS; RATS, INBRED BN; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 20144380062     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2214     Document Type: Article

References (37)

1. Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF α in combination with interferon-γ and melphalan in isolation perfusion. World J Surg 1992;16:234-40.
2. Eggermont AM, Schraffordt KH, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653-65.
3. Eggermont AM, Schraffordt KH, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-64.
4. Bickels J, Manusama ER, Gutman M, et al. Isolated limb perfusion with tumour necrosis factor-α and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol 1999;25:509-14.
5. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429-37.
6. Olieman AF, Lienard D, Eggermont AM, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor α, interferon γ, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999;134:303-7.
7. de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor α increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000-3.
8. de Wilt JH, Manusama ER, van Tiel ST, van Ijken MG, ten Hagen TL, Eggermont AM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor α and melphalan in rats. Br J Cancer 1999;80:161-6.
9. Manusama ER, Stavast J, Durante NM, Marquet RL, Eggermont AM. Isolated limb perfusion with TNF α and melphalan in a rat osteosarcoma model: a new antitumour approach. Eur J Surg Oncol 1996;22:152-7.
10. Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, Eggermont AM. Synergistic antitumour effect of recombinant human tumour necrosis factor α with melphalan in isolated limb perfusion in the rat. Br J Surg 1996;83:551-5.
11. van Der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-α augments intratumoural concentrations of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000;82;973-80.
12. van Etten B, de Vries MR, van Ijken MG, et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion. Br J Cancer 2003;88:314-9.
13. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 2003;95:741-9.
14. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
15. Winkelhake JL, Gauny SS. Human recombinant interleukin-2 as an experimental therapeutic. Pharmacol Rev 1990;42:1-28.
16. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193:1007-8.
17. Baselmans AH, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W. The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 2002;51:492-8.
18. Den Otter W, De Groot JW, Bernsen MR, et al. Optimal regimes for local IL-2 tumour therapy. Int J Cancer 1996;66:400-3.
19. Eton O, Rosenblum MG, Legha SS, et al. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer 2002;95:127-34.
20. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998;338:1272-8.
21. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-32.
22. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-56.
23. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
24. Tjaden UR, de Bruijn EA. Chromatographic analysis of anticancer drugs. J Chromatogr 1990;531:235-94.
25. Nooijen PT, Manusama ER, Eggermont AM, et al. Synergistic effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 1996;74:1908-15.
26. Atkins MB. Interleukin-2: clinical applications. Semin Oncol 2002;29:12-7.
27. Weidmann E, Sacchi M, Plaisance S, et al. Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res 1992;52:5963-70.
28. Rimoldi D, Salvi S, Hartmann F, et al. Expression of IL-2 receptors in human melanoma cells. Anticancer Res 1993;13:555-64.
29. Holzinger C, Weissinger E, Zuckermann A, et al. Effects of interleukin-1, -2, -4, -6, interferon-γ and granulocyte/macrophage colony stimulating factor on human vascular endothelial cells. Immunol Lett 1993;35:109-17.
30. Hicks C, Cooley MA, Penny R. Investigation of interleukin 2 receptors on human endothelial cells. Growth Factors 1991;5:201-8.
31. Kelley ST, Menon C, Buerk DG, Bauer TW, Fraker DL. Acidosis plus melphalan induces nitric oxide-mediated tumor regression in an isolated limb perfusion human melanoma xenograft model. Surgery 2002;132:252-8.
32. Skarsgard LD, Skwarchuk MW, Vinczan A, Kristl J, Chaplin DJ. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 1995;15:219-23.
33. Chaplin DJ, Acker B, Olive PL. Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys 1989;16:1131-5.
34. Economou JS, McBride WH, Essner R, et al. Tumour necrosis factor production by IL-2-activated macrophages in vitro and in vivo. Immunology 1989;67:514-9.
35. Maekawa H, Iwabuchi K, Nagaoka I, Watanabe H, Kamano T, Tsurumaru M. Activated peritoneal macrophages inhibit the proliferation of rat ascites hepatoma AH-130 cells via the production of tumor necrosis factor-α and nitric oxide. Inflamm Res 2000;49:541-7.
36. Albina JE, Reichner JS. Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis. Cancer Metastasis Rev 1998;17:39-53.
37. Bonnotte B, Larmonier N, Favre N, et al. Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol 2001;167:5077-83.